Overtraining Syndrome — Pathological Counterpart of the Lactate Shuttle

Table of Contents

1. Hormesis and the OT Continuum
2. Lactate Curve in OTS (Urhausen 1998, Meeusen 2013)
3. Autonomic Nervous System Markers
4. Gleeson’s Marker Framework (2002)
5. Gabriel et al. 1998 — Immunophenotyping
6. Acute OT + Clinical Immune Signature (Fry 1994, Hackney 2012)
7. Cytokine Hypothesis (Smith 2000)
8. Psychological Monitoring (Morgan 1987, Meeusen 2013)
9. ECSS/ACSM 2013 Consensus (Meeusen et al.)
10. Lactate Clearance: OTS vs. Post-Infectious Syndromes
11. Open Questions
12. Learning Objectives
13. References
14. One-Minute-Paper Topics

---

1. Hormesis and the OT Continuum

Exercise follows a biphasic dose–response (Radak 2008): sedentary and chronic-overload sit at the two damaging ends of the same curve. The hormetic sweet spot coincides with MLSS / IAS (Kindermann, §7 parent lecture).

Term	Recovery
FOR — planned overreaching → supercompensation	Days
NFOR — extreme overreaching, no supercompensation	Weeks – months
OTS — prolonged maladaptation, exclusion diagnosis	Months – years

Prevalence (Meeusen 2013): 7–21% per season; career rate ~60% in elite endurance athletes; 91% relapse after a first OTS episode.

---

2. Lactate Curve in OTS (Urhausen 1998, Meeusen 2013)

The lactate–power curve is NOT classically left-shifted in OTS. Instead:

• Submaximal lactate ↓ slightly (deceptively “improved”)
• Maximal lactate ↓
• Max HR ↓
• Time-to-exhaustion at 110% IAS ↓ ~27% ← most sensitive ergometric marker
• 10/30 s anaerobic alactacid power unchanged

A graded test alone misleads. Always combine with a supra-threshold time-to-exhaustion test plus a mood questionnaire.

---

3. Autonomic Nervous System Markers

Israel’s two-form model:

Form	Profile	ANS signature
Sympathicotonic OT	Strength/sprint, acute, young	↑ resting HR, ↑ BP, ↑ catecholamines, anxiety, insomnia
Parasympathicotonic OT	Endurance, chronic	↓ resting HR, depressed mood, fatigue — harder to diagnose

Sympathetic markers: ↓ max HR; ↑ LF/HF (short-term overload); ↓ nocturnal catecholamines (chronic); blunted lactate response; blunted cortisol/ACTH/GH/PRL to exercise.

Parasympathetic markers: ↑ HF power, ↑ RMSSD (Hedelin); ↓ resting HR in chronic endurance OTS.

Unifying mechanism — β-adrenergic receptor down-regulation (Gleeson, Lehmann): chronic catecholamine surges desensitize peripheral β-AR + central HPA, explaining the convergent blunting of max HR, max lactate, cortisol, and pituitary response. Probed directly by the two-bout test (§9).

Diagnostic caveat: HRV is inconsistent across studies — useful only as longitudinal trend in the same athlete (Meeusen 2013).

Link to lactate shuttle: the blunted submax/max lactate is a downstream consequence of sympathetic exhaustion, not a shuttle failure. MCT1/MCT4 machinery remains intact.

---

4. Gleeson’s Marker Framework (2002)

Criteria for an ideal OTS marker: sensitive to load, predictive, distinguishable from acute exercise, easy/cheap, non-invasive, measurable at rest or after a short submaximal bout.

Verdict — what works:

Marker	Status
Blunted cortisol response to standardized exercise	Best hormonal probe (saliva-based)
Blunted lactate response to fixed-intensity exercise	β-adrenergic / HPA dysregulation
CD4⁺CD45RO⁺ expression	High specificity + sensitivity (see §5)
Salivary IgA ↓	Good with caveats

What doesn’t work alone: plasma glutamine, CK, urea, cortisol/T ratio, resting catecholamines, CD4/CD8 ratio.

---

5. Gabriel et al. 1998 — Immunophenotyping

Companion to Urhausen 1998 (same Saarbrücken cohort). Flow cytometry of CD3/4/8/16/19/45/45RO/56/HLA-DR.

Key finding: peripheral T, B, NK cell counts are NOT altered in OTS. But receptor density of CD45RO on CD4⁺ T-cells is significantly elevated (P < 0.001).

• Self-learning classifier: specificity 92%, sensitivity 93%
• Count-based classification only: 67% / 84%
• Caveat: CD45RO ↑ also reflects subclinical viral (e.g. EBV) reactivation — always screen first
• Meeusen 2013 endorses CD45RO as the single most discriminating immune marker

---

6. Acute OT + Clinical Immune Signature (Fry 1994, Hackney 2012)

Acute OT (5 SAS soldiers, 10 days × 2 sessions/day): performance ↓, mood ↓, IL-2 + lymphocyte proliferation ↓. With recovery, mood normalizes — but fatigue and immune deficits persist.

OTS immune phenotype: ↓ NK cytotoxicity, ↓ neutrophil oxidative burst, ↓ T-cell proliferation, Th2 shift, ↓ sIgA, ↑ resting IL-6 (paradoxical), recurrent URTI, EBV/HSV reactivation, reduced vaccine response. >50% of pre-Olympic OT-symptomatic athletes present with infection vs. 0% of overreached controls.

---

7. Cytokine Hypothesis (Smith 2000)

Training overload → micro-trauma → monocyte activation
                       ↓
        Systemic IL-1β / IL-6 / TNF-α ↑
                       ↓
    CNS sickness behavior  +  Liver gluconeogenesis ↑
    HPA exhaustion         +  Immune dysfunction

OTS = Selye GAS stage 3 (exhaustion), not adaptation. Chronic inflammation downregulates PGC-1α and mitochondrial biogenesis — the same pathways the lactate shuttle (§4 parent) is designed to activate.

---

8. Psychological Monitoring (Morgan 1987, Meeusen 2013)

• POMS: dose-response with training load; iceberg profile inverts in staleness; up to 80% of OTS athletes show clinical depression
• TDS (7 items): higher discriminant accuracy than full POMS
• RESTQ-Sport (77 items, 19 factors): captures stress and recovery
• Psychomotor speed / reaction-time tests (Stroop, finger pre-cuing): detect central fatigue earlier than biochemistry

---

9. ECSS/ACSM 2013 Consensus (Meeusen et al.)

Two-Bout Maximal Exercise Test

Two incremental tests to exhaustion, separated by 4 hours. Hormonal pattern on bout 2 vs. bout 1:

State	ACTH / PRL / GH on bout 2
Healthy	Comparable
FOR	Less pronounced
NFOR	Hyperreactive
OTS	Bout 1 extreme + complete suppression in bout 2

The only protocol that prospectively differentiates NFOR from OTS.

Foster Session-RPE Load Model

• Daily load = session RPE × duration (min)
• Monotony = daily mean ÷ SD
• Strain = weekly load × monotony

Spikes in monotony/strain prospectively predict illness and injury.

Prevention (the only “treatment” is rest)

1. ≥ 1 passive rest day/week
2. Sleep hygiene
3. CHO 8.5 g/kg/day (Achten 2004); glutamine/BCAA supplementation does NOT help
4. Avoid monotony; individualize intensity (IAS-based)
5. Suspend training during URTI
6. Multidisciplinary monitoring for elite athletes

Diagnostic Flowchart

Underperformance ≥ 2 weeks
  → Rule out organic causes (CBC, ferritin, TSH, EBV/CMV, CK, allergies, cardiology)
  → Lactate test: submax ↓ + max ↓ + max HR ↓
  → 110% IAS time-to-exhaustion test (Urhausen) → t_exh ↓ ≥ 20%
  → Two-bout exercise test (Meeusen) → bout 2 suppression
  → Flow cytometry: CD45RO on CD4⁺ ↑↑ (rule out EBV)
  → POMS / TDS / RESTQ-Sport → TMD ↑, depression ↑↑
  → 2–4 weeks complete rest
        → recovery in weeks → NFOR
        → no recovery in months → OTS

---

10. Lactate Clearance: OTS vs. Post-Infectious Syndromes

Critical differential. OTS and ME/CFS / Long COVID look similar (fatigue, low max lactate) but have opposite clearance signatures.

Feature	OTS	ME/CFS / Long COVID
Lactate–power curve	No shift	Left-shifted
Resting lactate	Normal	↑ (correlates with PEM, Lien 2019)
Submax lactate (low W)	↓ or unchanged	↑
Max lactate	↓	↓
Post-exercise clearance	Largely preserved	Slower
2-day CPET VO₂ at AT (day 2)	Variable	Reproducibly ↓ (Snell 2013)
Peripheral O₂ extraction	Preserved	↓ (Haunhorst 2022)
Primary defect	Reduced production (β-AR / HPA)	Reduced clearance / oxidation (mitochondrial + microvascular)
Recovery	Months with rest	Often years; PEM after minimal effort

Mechanism in post-infectious syndromes (Haunhorst 2022, 2024; Joseph 2023; Singh 2022):

• Mitochondrial dysfunction (complex I/IV, PDH ↓; PCr resynthesis ↓)
• Reduced MCT1 expression in muscle subgroups
• Endothelial / microvascular dysfunction
• Autonomic dysregulation (POTS overlap)
• Failed lactate-mediated ETC activation (Cai 2023)
• Immunometabolic dysregulation (Haunhorst 2024)

Brooks-shuttle lens: OTS breaks the upstream sympathetic drive that fuels glycolytic production — shuttle machinery intact. Post-infectious syndromes break the downstream oxidative machinery that consumes lactate — the drain is plugged.

Therapeutic consequence (clinically critical):

• OTS → rest (Meeusen 2013)
• ME/CFS / Long COVID with PEM → pacing within energy envelope — graded exercise can worsen the condition (Haunhorst 2024)

Same lactate-curve abnormality at face value can require opposite therapy depending on whether the defect is autonomic exhaustion or mitochondrial-microvascular dysfunction.

Mixed phenotypes (overtrained athlete + EBV/SARS-CoV-2 infection) are common and require the Meeusen 2013 flowchart expanded with microvascular/immunometabolic work-up.

---

11. Open Questions

• MCT1/MCT4 expression in OTS muscle? (Brooks 2022)
• Histone lactylation as persistence mechanism?
• Does impaired lactate signaling underlie blunted T-cell response in OTS? (Cai 2023)
• OTS as non-infectious analog of PEM in ME/CFS / Long COVID?
• Sex differences + RED-S interactions under-studied
• Multicenter validation of two-bout test

---

12. Learning Objectives

You can:

1. Distinguish FOR / NFOR / OTS by recovery time
2. Recognize the paradoxically low submax + max lactate signature of OTS
3. Distinguish sympathicotonic vs. parasympathicotonic OT (Israel) and the β-AR mechanism
4. Apply Gleeson’s criteria to candidate markers
5. Explain the CD45RO receptor-density finding (Gabriel 1998)
6. State the cytokine hypothesis (Smith 2000)
7. Use POMS / TDS / RESTQ for early monitoring
8. Apply the ECSS/ACSM 2013 flowchart and two-bout test
9. Calculate session-RPE load, monotony, strain (Foster)
10. Recommend evidence-based prevention (rest, sleep, 8.5 g/kg/d CHO)
11. Differentiate OTS from ME/CFS / Long COVID via the lactate-clearance signature (Haunhorst 2022, 2024)
12. Recognize when graded exercise is contraindicated (PEM populations)

---

References

• Meeusen et al. (2013). ECSS/ACSM Joint Consensus on OTS. MSSE, 45(1), 186–205.
• Urhausen et al. (1998). Ergometric & psychological findings during overtraining. IJSM, 19, 114–120.
• Gabriel et al. (1998). Overtraining and immune system. MSSE, 30(7), 1151–1157.
• Gleeson (2002). Biochemical & immunological markers of overtraining. JSSM, 1, 31–41.
• Smith (2000). Cytokine hypothesis of overtraining. MSSE, 32(2), 317–331.
• Morgan et al. (1987). Psychological monitoring of overtraining and staleness. BJSM, 21(3), 107–114.
• Radak et al. (2008). Exercise, oxidative stress and hormesis. Ageing Res Rev, 7, 34–42.
• Fry et al. (1994). Psychological & immunological correlates of acute overtraining. BJSM, 28(4), 241–246.
• Hackney & Koltun (2012). Immune system & overtraining: clinical implications. Acta Clin Croat, 51, 633–641.
• Kreher & Schwartz (2012). Overtraining Syndrome: A Practical Guide. Sports Health, 4(2), 128–138.
• Israel S (1976). Zur Problematik des Übertrainings. Medizin und Sport, 16, 1–12.
• Lehmann et al. (1998). Autonomic imbalance hypothesis & OTS. MSSE, 30(7), 1140–1145.
• Hedelin et al. (2000). Cardiac autonomic imbalance in an overtrained athlete. MSSE, 32(9), 1531–1533.
• Bosquet et al. (2008). HR & overreaching: systematic review. BJSM, 42, 709–714.
• Foster (1998). Monitoring training with reference to OTS. MSSE, 30, 1164–1168.
• Achten et al. (2004). Higher CHO during intensified training. J Appl Physiol, 96, 1331–1340.
• Haunhorst S, … Puta C (2022). Long COVID: putative pathophysiology & physical activity. Oxford Open Immunology, 3(1), iqac006.
• Haunhorst S, … Puta C et al. (2024). Physical activity-induced PEM: microvascular alterations & immunometabolic interactions in post-COVID & ME/CFS. Infection.
• Lien et al. (2019). Elevated resting lactate correlates with PEM severity in ME/CFS. Sci Rep, 9, 19181.
• Singh et al. (2022). Persistent exertional intolerance after COVID-19: invasive CPET. Chest, 161(1), 54–63.
• Joseph et al. (2023). Exercise pathophysiology in ME/CFS and PASC. Chest, 164(3), 717–726.
• Snell et al. (2013). Discriminative validity of 2-day CPET in CFS. Phys Ther, 93(11), 1484–1492.

---

One-Minute-Paper Topics

1. Define FOR / NFOR / OTS; what single feature distinguishes them?
2. Position OTS on the hormesis curve and name the pathway(s) suppressed.
3. Why is OTS in most cases a retrospective diagnosis?
4. Does the OTS lactate curve shift left, right, or neither? Contrast with detraining / Long COVID.
5. Why is submax lactate sometimes ↓ in OTS, and why can this mislead?
6. Describe the 110% IAS time-to-exhaustion test and the threshold for OT suspicion.
7. Distinguish sympathicotonic vs. parasympathicotonic OT. Which dominates in endurance athletes?
8. Name three findings explained by β-adrenergic receptor down-regulation.
9. Why is HRV unreliable as a single OTS marker?
10. Recite Gleeson’s six criteria for an ideal OTS marker.
11. Why is a blunted cortisol response more informative than resting cortisol?
12. What did Gabriel 1998 measure that prior studies missed? Specificity/sensitivity?
13. Why screen EBV/CMV before attributing CD45RO↑ to OTS?
14. Summarize Smith’s cytokine hypothesis in five steps. Which Selye-GAS stage?
15. How does chronic inflammation blunt lactate-as-lactormone signaling?
16. Argue for or against: OTS as a non-infectious PEM analog.
17. Describe the two-bout test. What hormonal pattern distinguishes FOR/NFOR/OTS?
18. Calculate Foster monotony and strain for: 400, 420, 380, 410, 390, 400, 410 (RPE × min).
19. State the most important prevention strategy and the CHO recommendation (g/kg/day).
20. A fatigued athlete shows elevated resting lactate, left-shifted lactate-power curve, and reproducible day-2 VO₂ drop on 2-day CPET. OTS or post-infectious? What therapy is contraindicated, and why?